Blueprint Medicines (BPMC) Q3 2024 earnings summary

Executive summary

• AYVAKIT/Ayvakit revenue reached $128.2M in Q3 2024, up 137% year-over-year, with $113.1M from the US and $15.1M ex-US, and full-year guidance raised to $475–$480M.

• Net loss for Q3 2024 was $56.3M, a significant improvement from $133.7M in Q3 2023; nine-month net loss narrowed to $17.1M from $396.1M.

• Cash, cash equivalents, and investments totaled $882.4M as of September 30, 2024, supporting at least 12 months of operations.

• The company is advancing its mast cell portfolio, including BLU-808 and elenestinib, with key milestones on track for 2024 and early 2025.

• Completed transition of GAVRETO U.S. rights to Rigel and recognized a $173.7M debt extinguishment gain in 2024.

Financial highlights

• Q3 2024 total revenue was $128.2M, up from $56.6M in Q3 2023; nine-month revenue reached $362.5M.

• Product revenue for Q3 2024: $128.2M (U.S.: $113.1M; Rest of World: $15.1M); cost of sales decreased to $1.9M.

• R&D expenses fell to $85.3M from $110.3M; SG&A expenses increased to $89.9M from $70.7M.

• Net loss per share for Q3 2024 was $0.89, compared to $2.20 in Q3 2023.

• Cash used in operations for nine months: $163.2M, improved from $357.9M in 2023.

Outlook and guidance

• 2024 AYVAKIT/Ayvakit global net product revenue guidance raised to $475–$480M, reflecting strong sales momentum.

• Full-year operating expenses and cash burn expected to decline versus 2023.

• Company expects to initiate HARBOR Part 2 for elenestinib by year-end and present BLU-808 Phase 1 data in early 2025.

• Cash and investments expected to support a self-sustainable financial profile.

• International expansion, especially in Europe, is expected to drive further growth in 2025 and beyond.